SecurityEYEG / Eyegate Pharmaceuticals Inc. (30233M107)
Institutional Owners26 (2 N-Q Owners)
Institutional Shares21,125,607 - 50.74% (ex. N-Q)
Common Shares Outstanding41,635,005 shares (as of 2018-03-31)
Institutional Value$ 244,000 USD (ex. N-Q)

Institutional Stock Ownership and Shareholders

EYEG / Eyegate Pharmaceuticals Inc. Institutional Ownership

Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG) has 26 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 21,125,607 shares. Largest shareholders include Armistice Capital, Llc, Empery Asset Management, LP, Intracoastal Capital, Llc, Ipsa (innoven Partenaires S.a.), Vanguard Group Inc, Virtu Financial LLC, Citadel Advisors Llc, Barclays Plc, Us Bancorp \de\, and Bank of New York Mellon Corp.
Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/eyeg"><img src="https://images.fintel.io/us-eyeg-so.png" alt="EYEG / Eyegate Pharmaceuticals Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 16,671 6
2018-05-15 13F-HR UBS Group AG 4,400 1,537 -65.07 5 1 -80.00
2018-04-23 SC 13G INTRACOASTAL CAPITAL, LLC 1,562,500
2018-02-14 13F-HR MORGAN STANLEY 740 740 0.00 1 1 0.00
2018-05-11 13F-HR MACQUARIE GROUP LTD 25,400 0 -100.00 27 0 -100.00
2018-02-09 13F-HR Virtu Financial LLC 15,967 71,910 350.37 19 77 305.26
2018-02-27 N-Q Blackstone Alternative Investment Funds (see advisory)
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 1 12,356 1,235,500.00 0 5
2018-05-01 13F-HR WEDBUSH SECURITIES INC 20,000 20,000 0.00 21 8 -61.90
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 304 9,226 2,934.87 0 4
2018-02-28 N-Q Ishares Trust (see advisory)
2018-01-17 SC 13D/A IPSA (INNOVEN PARTENAIRES S.A.) 1,045,279 770,065 -26.33
2018-03-14 13F-HR/A CREDIT SUISSE AG/ 30,000 20,000 -33.33 35 21 -40.00
2018-05-09 13F-HR BlackRock Inc. 635 635 0.00 1 0 -100.00
2018-02-09 13F-HR Holistic Financial Partners 1,900 2
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 30,483 12,603 -58.66 33 5 -84.85
2018-04-03 13F-HR Washington Trust Bank 1,700 0 -100.00 2 0 -100.00
2018-05-09 13F-HR NORTHERN TRUST CORP 14,553 14,553 0.00 16 6 -62.50
2018-02-15 13F-HR/A Sabby Management, LLC 46,378 0 -100.00 54 0 -100.00
2018-05-15 13F-HR Bank of New York Mellon Corp 28,835 11
2018-05-17 SC 13D/A ARMISTICE CAPITAL, LLC 16,246,978 16,742,500 3.05
2018-05-10 13F-HR Vantage Investment Advisors, LLC 6,500 6,500 0.00 7 2 -71.43
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 600 100 -83.33 1 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 52,569 20
2018-01-16 SC 13G/A Empery Asset Management, LP 1,500,000 1,582,380 5.49
2018-05-09 13F-HR IFP Advisors, Inc 23,800 26,800 12.61 25 10 -60.00
2018-05-08 13F-HR US BANCORP \DE\ 40,650 15
2018-05-15 13F-HR VANGUARD GROUP INC 268,119 73,949 -72.42 287 28 -90.24
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 32,169 56,628 76.03 34 22 -35.29
2018-02-14 13F-HR BANK OF AMERICA CORP /DE/ 524 0 -100.00 1 0 -100.00

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.

Limitations:

  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( EYEG / Eyegate Pharmaceuticals Inc. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

14h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

14h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Reader Inquiry: Time To Buy EyeGate Pharmaceuticals?

2018-05-18 seekingalpha
Shares of fallen nearly 70% year to date but appear to be ready to fill the gap back to the psychologically important $1 level. (22-1)

Your Daily Pharma Scoop: Intercept's OCA, MediciNova In NASH, Pulse Biosciences Data

2018-04-16 seekingalpha
Intercept Pharmaceuticals (ICPT) reported clinical data from a liver biopsy-based substudy from its phase 3 POISE study. The study indicated that long-term OCA treatment in patients with PBC led to reversal or stabilization of fibrosis and cirrhosis. (143-3)

Office Depot, Dominion Energy Fall into Friday’s 52-Week Low Club

2018-04-13 247wallst
April 13, 2018: Here are four stocks trading with heavy volume among 52 equities making new 52-week lows in Friday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners led advancers by about 9 to 5. (19-0)

Your Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo Setback

2018-04-10 seekingalpha
Today we will discuss Acadia Pharmaceuticals (NASDAQ:ACAD), which has fallen sharply on a CNN report that raised concerns about the Nuplazid’s safety. (210-4)

Your Daily Pharma Scoop: Major Setback For Incyte, Aclaris Agreement, MannKind Offering

2018-04-07 seekingalpha
Incyte (NASDAQ:INCY) shares tumbled more than 17% as investors digested the disappointing news with regard to the company’s phase 3 study evaluating the Epacadostat/Keytruda combination in patients with unresectable or metastatic melanoma. (154-0)

CUSIP: 30233M107